FMA
FLNA

FNY Managed Accounts’s Filana Therapeutics FLNA Stock Holding History

FNY Managed Accounts’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,571
Closed -$43K – 280
2014
Q3 		$43K Buy
+1,571
New +$47.7K 0.13% 98

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FNY Managed Accounts's FLNA Position: Q4 2014 in Review

FNY Managed Accounts sold out of Filana Therapeutics (FLNA) in Q4 2014, closing a stake of 1,571 shares — an estimated $43K sold.

FNY Managed Accounts first reported a position in FLNA in Q3 2014 and held it in 1 quarter. The position peaked at $43K in Q3 2014. 66 funds tracked by Wall St. Rank hold FLNA as of Q4 2014.

  • FNY Managed Accounts reported no remaining Filana Therapeutics position as of Q4 2014 after selling out during the quarter.
  • FNY Managed Accounts sold 1,571 Filana Therapeutics shares in Q4 2014, an estimated $43K.
  • FNY Managed Accounts first reported a position in Filana Therapeutics in Q3 2014 and held it in 1 quarter.
  • FNY Managed Accounts's Filana Therapeutics position peaked at $43K in Q3 2014.
  • 66 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2014.

Based on FNY Managed Accounts's 13F filing for Q4 2014, filed 9 Jan 2015.